JP2016528195A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528195A5 JP2016528195A5 JP2016523819A JP2016523819A JP2016528195A5 JP 2016528195 A5 JP2016528195 A5 JP 2016528195A5 JP 2016523819 A JP2016523819 A JP 2016523819A JP 2016523819 A JP2016523819 A JP 2016523819A JP 2016528195 A5 JP2016528195 A5 JP 2016528195A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- antibody
- cells
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 41
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 201000011510 cancer Diseases 0.000 claims description 32
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 31
- 108010056102 CD100 antigen Proteins 0.000 claims description 24
- 102100027744 Semaphorin-4D Human genes 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 19
- 230000002519 immonomodulatory effect Effects 0.000 claims description 17
- 238000002560 therapeutic procedure Methods 0.000 claims description 17
- 102100034384 Plexin-B1 Human genes 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 101150029707 ERBB2 gene Proteins 0.000 claims description 7
- 101001067174 Homo sapiens Plexin-B1 Proteins 0.000 claims description 7
- 101001067170 Homo sapiens Plexin-B2 Proteins 0.000 claims description 7
- 102100034383 Plexin-B2 Human genes 0.000 claims description 7
- 230000005746 immune checkpoint blockade Effects 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 229940022399 cancer vaccine Drugs 0.000 claims description 5
- 238000009566 cancer vaccine Methods 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 101710100559 Plexin-B1 Proteins 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- 238000009175 antibody therapy Methods 0.000 claims description 3
- 201000000053 blastoma Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 201000008184 embryoma Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 229960001438 immunostimulant agent Drugs 0.000 claims description 3
- 239000003022 immunostimulating agent Substances 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000002628 peritoneum cancer Diseases 0.000 claims description 3
- 210000003289 regulatory T cell Anatomy 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 238000002659 cell therapy Methods 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000002022 plexin Human genes 0.000 claims 2
- 108050009312 plexin Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000005911 anti-cytotoxic effect Effects 0.000 claims 1
- 230000000781 anti-lymphocytic effect Effects 0.000 claims 1
- 238000003782 apoptosis assay Methods 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000005522 programmed cell death Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 62
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361839170P | 2013-06-25 | 2013-06-25 | |
| US61/839,170 | 2013-06-25 | ||
| US201361874241P | 2013-09-05 | 2013-09-05 | |
| US61/874,241 | 2013-09-05 | ||
| US201361884771P | 2013-09-30 | 2013-09-30 | |
| US61/884,771 | 2013-09-30 | ||
| US201361907845P | 2013-11-22 | 2013-11-22 | |
| US61/907,845 | 2013-11-22 | ||
| PCT/US2014/043466 WO2014209802A1 (en) | 2013-06-25 | 2014-06-20 | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129005A Division JP7021153B2 (ja) | 2013-06-25 | 2019-07-11 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016528195A JP2016528195A (ja) | 2016-09-15 |
| JP2016528195A5 true JP2016528195A5 (enExample) | 2017-07-27 |
| JP6611709B2 JP6611709B2 (ja) | 2019-11-27 |
Family
ID=52142579
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016523819A Active JP6611709B2 (ja) | 2013-06-25 | 2014-06-20 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用 |
| JP2019129005A Active JP7021153B2 (ja) | 2013-06-25 | 2019-07-11 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用 |
| JP2022015562A Active JP7356531B2 (ja) | 2013-06-25 | 2022-02-03 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129005A Active JP7021153B2 (ja) | 2013-06-25 | 2019-07-11 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用 |
| JP2022015562A Active JP7356531B2 (ja) | 2013-06-25 | 2022-02-03 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US9828435B2 (enExample) |
| EP (2) | EP3013350B1 (enExample) |
| JP (3) | JP6611709B2 (enExample) |
| KR (2) | KR102291971B1 (enExample) |
| CN (1) | CN105492016B (enExample) |
| AU (2) | AU2014302812B2 (enExample) |
| BR (1) | BR112015032690B1 (enExample) |
| CA (2) | CA2916245C (enExample) |
| DK (1) | DK3013350T3 (enExample) |
| EA (1) | EA036591B1 (enExample) |
| ES (1) | ES2782834T3 (enExample) |
| IL (1) | IL243301B (enExample) |
| MX (1) | MX377858B (enExample) |
| NZ (1) | NZ631015A (enExample) |
| PL (1) | PL3013350T3 (enExample) |
| PT (1) | PT3013350T (enExample) |
| SG (2) | SG10201902380SA (enExample) |
| WO (1) | WO2014209802A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG175417A1 (en) | 2009-05-08 | 2011-12-29 | Vaccinex Inc | Anti-cd100 antibodies and methods for using the same |
| CN110105452A (zh) | 2011-10-11 | 2019-08-09 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| ES2776698T3 (es) | 2012-12-20 | 2020-07-31 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| EP3013350B1 (en) | 2013-06-25 | 2020-01-08 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| US10278984B2 (en) * | 2014-05-02 | 2019-05-07 | Nitor Therapeutics | Guanosine as an immune potentiator mediated through toll receptors |
| US10973843B2 (en) | 2016-01-27 | 2021-04-13 | University Of Maryland, Baltimore | Method for monitoring cancer and for regulation of semaphorin 4D to improve cancer immunotherapy regimens |
| EP3213768A1 (en) | 2016-03-01 | 2017-09-06 | LODOCO CLINICAL Kft | Combination of low dose immune checkpoint blockade with high dose il-2 for treating metastatic cancer |
| WO2017177149A2 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| KR102403660B1 (ko) * | 2016-04-18 | 2022-05-30 | 파론 파머수티컬스 오와이 | CLEVER-1, TNF-α 및 HLA-DR 결합제를 사용하는 면역 활성화의 진단 |
| CA3018990A1 (en) | 2016-04-22 | 2017-10-26 | Vaccinex, Inc. | Integral membrane protein display on poxvirus extracellular enveloped virions |
| JP6656661B2 (ja) | 2016-06-16 | 2020-03-04 | 国立大学法人 東京大学 | プレキシンの結合調節剤 |
| WO2018026715A1 (en) | 2016-08-02 | 2018-02-08 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| USD889258S1 (en) * | 2016-08-04 | 2020-07-07 | Carolin McKie | Beverage container identification marker kit |
| CN110300598A (zh) * | 2016-09-16 | 2019-10-01 | 布里格姆妇女医院有限公司 | Klrg1消耗治疗 |
| RU2755903C2 (ru) | 2016-10-12 | 2021-09-22 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Способы и композиции для tusc2-иммунотерапии |
| WO2018148224A1 (en) | 2017-02-07 | 2018-08-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (ple) car t cell tumor targeting (ctct) agents |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| WO2018175179A1 (en) * | 2017-03-20 | 2018-09-27 | Vaccinex, Inc. | Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent |
| AU2018256436B2 (en) | 2017-04-19 | 2024-12-05 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| CN110636858B (zh) | 2017-05-05 | 2024-03-19 | 瓦西尼斯公司 | 人抗脑信号蛋白4d抗体 |
| WO2019144091A1 (en) | 2018-01-22 | 2019-07-25 | Endocyte, Inc. | Methods of use for car t cells |
| WO2019156795A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| EP3693380A1 (en) * | 2019-02-11 | 2020-08-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Dual inhibition of plexin-b1 and plexin-b2 |
| JP7362767B2 (ja) * | 2019-03-28 | 2023-10-17 | バクシネックス インコーポレーティッド | がん療法で使用するためのセマフォリン－４ｄアンタゴニスト |
| AU2020297592A1 (en) * | 2019-06-21 | 2022-01-06 | H. Lee Moffitt Cancer Center and Research Institute, Inc. (A Florida Non-Profit Corporation) | Combination therapy with Semaphorin-4D blockade (SEMA4D) and DC1 therapy |
| CA3152371A1 (en) | 2019-08-01 | 2021-02-04 | Vaccinex, Inc. | Combined inhibition of semaphorin-4d and tgf.beta. and compositions therefor |
| WO2021024020A1 (en) * | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CN111158663B (zh) * | 2019-12-26 | 2021-07-02 | 深圳逻辑汇科技有限公司 | 用于处理程序代码中的变量的引用的方法和系统 |
| WO2021262564A1 (en) * | 2020-06-25 | 2021-12-30 | Vaccinex, Inc. | Use of semaphorin-4d binding molecules for the treatment of rett syndrome |
| US20230390345A1 (en) * | 2020-08-21 | 2023-12-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Combination therapy comprising her-2-dc1 vaccine, a probiotic, and semaphorin |
| CN112233123B (zh) * | 2020-09-21 | 2024-05-14 | 广州金域医学检验中心有限公司 | 病理图片中肿瘤间质分类方法、装置、计算机设备及存储介质 |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| WO2023012314A1 (en) * | 2021-08-05 | 2023-02-09 | Lifearc | Anti-plexin-b1 antibodies |
| CN117802242A (zh) * | 2024-01-22 | 2024-04-02 | 深圳慕光生物科技有限公司 | 一种利用sema4d基因预测肿瘤免疫逃避风险的方法 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| KR100870353B1 (ko) | 1997-04-07 | 2008-11-25 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| CA2286477A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| JP4451987B2 (ja) | 1998-11-10 | 2010-04-14 | ユニバーシティー オブ ロチェスター | 標的抗原に特異的なｔ細胞ならびにこれに基づく方法およびワクチン |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| EP1423428B2 (en) | 2001-06-20 | 2012-11-14 | Fibron Ltd. | Antibodies that block fgfr3 activation, methods of screening for and uses thereof |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| WO2003101485A1 (en) | 2002-05-30 | 2003-12-11 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| RS20160203A1 (sr) | 2003-05-30 | 2016-10-31 | Genentech Inc | Tretman sa anti-vegf antitelima |
| CN1913921B (zh) | 2003-12-04 | 2012-02-22 | 瓦西尼斯公司 | 通过靶定暴露在细胞凋亡肿瘤细胞上的内部抗原杀死肿瘤细胞的方法 |
| CA2548282A1 (en) | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
| AU2005267720B2 (en) * | 2004-08-05 | 2012-02-23 | Genentech, Inc. | Humanized anti-cmet antagonists |
| US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| WO2006110594A2 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Sema4d in cancer diagnosis, detection and treatment |
| JP5838021B2 (ja) | 2005-04-15 | 2015-12-24 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディとその使用 |
| JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
| US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| ATE494306T1 (de) * | 2007-02-14 | 2011-01-15 | Vaccinex Inc | Humanisierte anti-cd100-antikörper |
| JP5357782B2 (ja) | 2007-02-21 | 2013-12-04 | バクシネックス インコーポレーティッド | 抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節 |
| NZ586544A (en) | 2007-12-26 | 2012-07-27 | Vaccinex Inc | Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods |
| TW200934512A (en) | 2008-01-10 | 2009-08-16 | Genentech Inc | PLEXIND1 agonists and their use |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| SG175417A1 (en) | 2009-05-08 | 2011-12-29 | Vaccinex Inc | Anti-cd100 antibodies and methods for using the same |
| AU2010248761B2 (en) | 2009-05-15 | 2016-02-11 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
| NZ605260A (en) | 2010-06-14 | 2013-12-20 | Joseph King Allan | Anti-vegf antibodies and uses thereof |
| AU2011295902B2 (en) | 2010-09-02 | 2014-12-04 | Vaccinex, Inc. | Anti-CXCL13 antibodies and methods of using the same |
| WO2012157237A1 (ja) | 2011-05-13 | 2012-11-22 | 国立大学法人東京医科歯科大学 | 骨形成促進剤 |
| EP2764023A4 (en) | 2011-10-06 | 2015-06-10 | Univ Texas | ANTI-HUMAN-SEMA4A ANTIBODY FOR THE TREATMENT OF ILLNESSES |
| CN110105452A (zh) | 2011-10-11 | 2019-08-09 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| CA2762446C (en) * | 2011-12-06 | 2021-02-23 | Vaccinex, Inc. | Use of the combination of semaphorin-4d inhibitory molecules and vegf inhibitory molecules to inhibit angiogenesis |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| AU2013225812B2 (en) | 2012-03-02 | 2017-11-30 | Vaccinex, Inc. | Methods for the treatment of B cell-mediated inflammatory diseases |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| EP2951204B1 (en) | 2013-01-31 | 2019-05-22 | Vaccinex, Inc. | Methods for increasing immunoglobulin a levels |
| US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
| EP3013350B1 (en) | 2013-06-25 | 2020-01-08 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| CA3018990A1 (en) | 2016-04-22 | 2017-10-26 | Vaccinex, Inc. | Integral membrane protein display on poxvirus extracellular enveloped virions |
| WO2018026715A1 (en) | 2016-08-02 | 2018-02-08 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| AU2018225493B2 (en) | 2017-02-22 | 2025-03-06 | Vaccinex, Inc. | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
-
2014
- 2014-06-20 EP EP14818498.9A patent/EP3013350B1/en active Active
- 2014-06-20 CA CA2916245A patent/CA2916245C/en active Active
- 2014-06-20 EA EA201690080A patent/EA036591B1/ru unknown
- 2014-06-20 KR KR1020167001991A patent/KR102291971B1/ko active Active
- 2014-06-20 AU AU2014302812A patent/AU2014302812B2/en active Active
- 2014-06-20 SG SG10201902380SA patent/SG10201902380SA/en unknown
- 2014-06-20 CN CN201480047166.7A patent/CN105492016B/zh active Active
- 2014-06-20 EP EP19209162.7A patent/EP3656392A1/en active Pending
- 2014-06-20 SG SG11201510505VA patent/SG11201510505VA/en unknown
- 2014-06-20 PL PL14818498T patent/PL3013350T3/pl unknown
- 2014-06-20 US US14/892,099 patent/US9828435B2/en active Active
- 2014-06-20 JP JP2016523819A patent/JP6611709B2/ja active Active
- 2014-06-20 KR KR1020217025537A patent/KR20210104166A/ko not_active Ceased
- 2014-06-20 BR BR112015032690-0A patent/BR112015032690B1/pt active IP Right Grant
- 2014-06-20 PT PT148184989T patent/PT3013350T/pt unknown
- 2014-06-20 DK DK14818498.9T patent/DK3013350T3/da active
- 2014-06-20 ES ES14818498T patent/ES2782834T3/es active Active
- 2014-06-20 WO PCT/US2014/043466 patent/WO2014209802A1/en not_active Ceased
- 2014-06-20 US US14/310,848 patent/US9243068B2/en active Active
- 2014-06-20 MX MX2015017485A patent/MX377858B/es unknown
- 2014-06-20 NZ NZ631015A patent/NZ631015A/en unknown
- 2014-06-20 CA CA3098741A patent/CA3098741A1/en active Pending
-
2015
- 2015-12-23 IL IL243301A patent/IL243301B/en active IP Right Grant
-
2017
- 2017-08-01 US US15/666,133 patent/US10526414B2/en active Active
-
2019
- 2019-04-23 US US16/392,451 patent/US11078295B2/en active Active
- 2019-07-11 JP JP2019129005A patent/JP7021153B2/ja active Active
- 2019-07-26 AU AU2019208274A patent/AU2019208274A1/en not_active Abandoned
-
2021
- 2021-06-29 US US17/362,020 patent/US12070500B2/en active Active
-
2022
- 2022-02-03 JP JP2022015562A patent/JP7356531B2/ja active Active
-
2024
- 2024-07-18 US US18/777,075 patent/US20250032609A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528195A5 (enExample) | ||
| Lazăr et al. | Prognostic significance of tumor immune microenvironment and immunotherapy: novel insights and future perspectives in gastric cancer | |
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| Kohrt et al. | Targeting CD137 enhances the efficacy of cetuximab | |
| Bell et al. | OX40 signaling in head and neck squamous cell carcinoma: overcoming immunosuppression in the tumor microenvironment | |
| Economopoulou et al. | The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches | |
| Parmar et al. | Immunotherapy in head and neck squamous cell carcinoma: An updated review | |
| Goel et al. | Cancer immunotherapy in clinical practice—the past, present, and future | |
| RU2019115428A (ru) | Способы лечения рака, включающие связывающие tigit агенты | |
| FI3313441T3 (fi) | Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla | |
| JP2019519499A5 (enExample) | ||
| JP2020534250A5 (enExample) | ||
| CN108473578A (zh) | 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合 | |
| JP2020528750A5 (enExample) | ||
| RU2014111999A (ru) | Антитела к C10RF32 и их применения для лечения рака | |
| JP2016525117A5 (enExample) | ||
| FI3455259T3 (fi) | Anti-PD-1-vasta-aineiden ja sädehoidon yhdistelmä syövän hoitoon | |
| KR20220082097A (ko) | 방사선 치료와 조합된 ｐｄ-1 및 ｐｄ-ｌ1에 대한 길항제를 이용하는 암 치료 방법 | |
| Rini | Future approaches in immunotherapy | |
| JP2018503365A5 (enExample) | ||
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| RU2017120063A (ru) | Терапевтические комбинации для лечения неоплазии | |
| JP7548924B2 (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| RU2019104980A (ru) | Анти-icos антитела | |
| JPWO2019157332A5 (enExample) |